文献速递前列腺癌男科与性医学

前列腺癌雄激素剥夺治疗与痴呆风险:更新系统综述与荟萃分析

Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-08-19

结果显示ADT与痴呆风险增加21%相关(合并HR=1.21,95%CI: 1.13-1.30,P<0.001),不同ADT类型均呈正相关,但口服抗雄激素和联合雄激素阻断未达统计学显著。

要点

  • ADT使用与前列腺癌患者痴呆风险增加21%相关(HR=1.21)。
  • 黄体生成素释放激素激动剂和双侧睾丸切除术与痴呆风险正相关。
  • 口服抗雄激素和联合雄激素阻断与痴呆风险正相关但未达统计学显著。

核心结论

  • ADT使用无论何种类型均与前列腺癌患者痴呆风险相关。
  • 未来需研究确定ADT是导致痴呆还是仅与风险增加相关。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、PubMed、Cochrane图书馆和Web of Science至2020年3月。
  • 使用风险比(HR)和95%置信区间(CI)作为效应量,采用I2统计量检验异质性。

主要发现

  • ADT使用与痴呆风险增加21%相关(合并HR=1.21,95%CI: 1.13-1.30,P<0.001)。
  • 黄体生成素释放激素激动剂与痴呆风险正相关(HR=1.14,P<0.001)。
  • 双侧睾丸切除术与痴呆风险正相关(HR=1.42,P<0.001)。
  • 口服抗雄激素与痴呆风险正相关(HR=1.35,P=0.138),差异未达统计学显著。
  • 联合雄激素阻断与痴呆风险正相关(HR=1.22,P=0.097),差异未达统计学显著。

临床怎么用

  • 在前列腺癌患者启动ADT前应评估痴呆风险,并在治疗中关注认知功能变化。
  • 不同ADT类型均与痴呆风险相关,选择方案时需综合权衡获益与风险。

局限性

  • 研究为观察性证据,无法确定ADT与痴呆的因果关系。
  • 口服抗雄激素和联合雄激素阻断亚组差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) administration was recently reported and might be positively associated with dementia. However, the existing studies showed controversial results. The aim of this study was to evaluate the relationship between ADT and the risk of dementia through a meta-analysis. METHODS: Original articles published up to March 2020 were retrieved from Embase, Pubmed, the Cochrane library, and Web of Science for studies focusing on associations between ADT for prostate cancer (PCa) and incidence of dementia. A meta-analysis was conducted using a hazard ratio (HR) and 95% confidence interval (CI) as effect measures. Heterogeneity between the studies was examined using I2 statistics. Subgroup analyses, sensitivity analyses, and meta-regression were conducted, and publication bias was assessed by Egger's test. RESULTS: Thirteen studies were included in this systematic review. Eleven cohort studies involving 339,400 cases and 436,851 controls were included in the main meta-analysis. ADT administration was associated with a 21% increase in dementia risk (pooled HR = 1.21, 95% CI: 1.13-1.30, P < 0.001). Subgroup analyses based on ADT types showed that luteinizing hormone-releasing hormone agonists (HR = 1.14, P < 0.001), bilateral orchiectomy (HR = 1.42, P < 0.001), oral antiandrogens (HR = 1.35, P = 0.138), and combined androgen blockade (HR = 1.22, P = 0.097) were positively related to subsequent risk of dementia, although the differences were not statistically significant with oral antiandrogens and combined androgen blockade. CONCLUSIONS: The current study indicated that ADT administration, no matter with types of ADT, is associated with the risk of dementia in patients with PCa. Future studies are needed to determine whether ADT causes dementia or is merely associated with increased risk.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Cui H, Wang Y, Li F, et al. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2020. PMID: 32814845. doi:10.1038/s41391-020-00267-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。